
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc. has demonstrated impressive year-over-year revenue growth, reporting a 31% increase in Q3 FY25 revenue to $18,942, significantly driven by an 89% rise in Nociscan report volumes. The company's strategic investments in sales and marketing, which increased by 172% year-over-year, highlight a commitment to enhancing market penetration and supporting its upcoming CLARITY trial, thereby setting the stage for long-term growth. Furthermore, Aclarion is experiencing momentum through new commercial agreements with reputable medical institutions, alongside favorable coverage decisions in the UK, suggesting a robust upward trajectory for the adoption of its Nociscan platform.
Bears say
Aclarion Inc. faces significant financial risks stemming from slow adoption of its Nociscan product by both surgeons and payers, coupled with escalating marketing and administrative expenses, which could hinder revenue growth. The company's financial outlook has been negatively adjusted multiple times, with the FY25 earnings per share (EPS) estimates lowered to $(15.13) and $(15.08), reflecting increased operational costs that exceed prior estimates. Furthermore, potential challenges such as balance sheet and liquidity risks, regulatory approval failures, and difficulties in securing reimbursement underscore the ongoing uncertainty surrounding Aclarion's ability to commercialize its product effectively.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares